<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-360 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-360</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-360</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-7.html">extraction-schema-7</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of population differences in the prevalence of activating EGFR mutations in lung cancer and proposed reasons for higher frequency in East Asians. Include quantitative evidence about mutation frequencies by ancestry, smoking status, sex, and age; germline variants and their allele frequencies/associations; environmental and hormonal exposures; mutational signatures and tumor mutation burden; co-mutation patterns; and differential response to EGFR-TKIs by ethnicity. Capture study design, methods, and any counter-evidence or limitations.</div>
                <p><strong>Paper ID:</strong> paper-8610522</p>
                <p><strong>Paper Title:</strong> The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases</p>
                <p><strong>Paper Abstract:</strong> Background. Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). The selection of chemotherapy based on the EGFR mutation status is recommended, however, the frequency of EGFR mutation in patients with ILD and the efficacy and safety of EGFR-TKI in patients with ILD and EGFR mutation are unknown. Methods. We retrospectively reviewed the association of the EGFR mutation status of nonsmall cell lung cancer and pulmonary diseases. Based on high-resolution computed tomography (HRCT) performed at diagnosis of lung cancer, patients were categorized into three groups: normal, emphysema, and fibrosis. Results. Of 198 patients with nonsmall cell lung cancer, we identified 52 (26.3%) patients with an EGFR mutation. EGFR mutations were identified in 43 (35.2%) of 122 patients with normal lungs, 8 (13.6%) of 59 with emphysema, and 1 (5.9%) of 17 with pulmonary fibrosis. Of the 52 patients with EGFR mutation, 43 patients received gefitinib. One patient with an EGFR mutation and fibrosis developed fatal ILD. There was not a significant difference in median overall survival from gefitinib treatment between never-smokers and smokers (797 days versus not reached; P = 0.96). Conclusions. Patients with sensitive EGFR mutation and normal lungs may benefit from an EGFR-TKI treatment even if they have smoking history.</p>
                <p><strong>Cost:</strong> 0.01</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e360.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e360.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of population differences in the prevalence of activating EGFR mutations in lung cancer and proposed reasons for higher frequency in East Asians. Include quantitative evidence about mutation frequencies by ancestry, smoking status, sex, and age; germline variants and their allele frequencies/associations; environmental and hormonal exposures; mutational signatures and tumor mutation burden; co-mutation patterns; and differential response to EGFR-TKIs by ethnicity. Capture study design, methods, and any counter-evidence or limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Usui2011</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Clinical Study The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Single-institution retrospective study (NTT Medical Center Tokyo) that measured prevalence of sensitizing EGFR kinase-domain mutations in 198 NSCLC patients and analyzed associations with sex, smoking history, histology, age, and chest HRCT-defined pulmonary disease (normal, emphysema, fibrosis); also reports on outcomes with gefitinib in mutation-positive patients.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Clinical Study The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_identifier</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Clinical Study The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases</td>
                        </tr>
                        <tr>
                            <td><strong>publication_year</strong></td>
                            <td>2011</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Single-institution retrospective clinical cohort with targeted EGFR mutation testing (peptide nucleic acid-locked nucleic acid PCR clamp); prospective chest HRCT classification of pulmonary comorbidities; survival follow-up for gefitinib-treated mutation-positive patients.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_context</strong></td>
                            <td>Japan; single-institution (NTT Medical Center Tokyo).</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_histology</strong></td>
                            <td>NSCLC overall (predominantly adenocarcinoma: 169/198); small numbers of squamous and other NSCLC subtypes.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_tumor</strong></td>
                            <td>198</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry_groups</strong></td>
                            <td>Japanese patients (East Asian population from single Japanese center). Ancestry was not genetically inferred or compared to other ancestry groups (self-report/clinical context implied).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency_overall</strong></td>
                            <td>52 of 198 patients (26.3%) had EGFR-TKI-sensitive EGFR mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency_by_group</strong></td>
                            <td>By sex: Male 17/112 (15.2%); Female 35/86 (40.7%) (P < 0.0001). By age: <65: 23/80 (28.8%); >=65: 29/118 (24.6%) (P = 0.5156). By histology: Adenocarcinoma 50/169 (29.6%); Non-adenocarcinoma 2/29 (6.9%) (P = 0.0107). By smoking: Never-smokers 29/74 (39.2%); Ex/current smokers 23/124 (18.5%) (P = 0.0139). By clinical stage: I-IIIA 21/63 (33.3%); IIIB-IV 31/135 (22.9%) (P = 0.1649). By chest CT pulmonary status: Normal lungs 43/122 (35.2%); Emphysema 8/59 (13.6%); Fibrosis 1/17 (5.8%) (P = 0.0011). Within the subgroup with normal lungs, EGFR mutation frequency in never-smokers = 26/69 (37.7%) vs smokers = 17/53 (32.1%) (P = 0.5698).</td>
                        </tr>
                        <tr>
                            <td><strong>effect_size_ethnic_difference</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>difference_persists_in_never_smokers</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>difference_persists_after_adjustment</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_subtypes_distribution</strong></td>
                            <td>Among the 52 EGFR-mutant tumors: Exon 19 deletions 34/52 (65.4%); Exon 21 L858R 15/52 (28.8%); Exon 18 G719S 1/52 (1.9%); compound Ex19del + Ex21 L858R 1/52 (1.9%); Ex19del + Ex20 T790M 1/52 (1.9%). The paper does not report subtype distribution stratified by ancestry (single-Japanese cohort) beyond these counts.</td>
                        </tr>
                        <tr>
                            <td><strong>co_mutation_landscape</strong></td>
                            <td>Not reported. The study did not perform broader genomic profiling or report co-mutations (e.g., TP53, KRAS) or mutual exclusivity patterns.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_spectrum</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>mutational_signatures</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_exposures_assessed</strong></td>
                            <td>Smoking history was recorded and analyzed (never vs ex/current; pack-years reported for gefitinib-treated smokers median 33, range 2.5â€“225). No other environmental exposures (cooking fumes, coal, radon, air pollution, TB scars, occupational exposures) were assessed or analyzed for association with EGFR-mutant status in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>hormonal_factors</strong></td>
                            <td>Not measured or analyzed. The introduction cites female sex as a clinical predictor, but no hormonal exposure data (e.g., hormone therapy, estrogen levels, ER expression) were collected in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_variants_and_haplotypes</strong></td>
                            <td>Not assayed. The authors mention prior literature identifying susceptibility loci (e.g., nicotinic acetylcholine receptor genes on 15q25 cited) as possible relevant genetic factors but did not measure germline variants, allele frequencies, or associations in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>inherited_egfr_pathogenic_variants</strong></td>
                            <td>Not reported. The study detected one tumor with Ex19del + Ex20 T790M (somatic/ tumor test) but did not report germline T790M or other inherited EGFR pathogenic variants.</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>Not assessed. Authors hypothesize overlap between smoking-related pulmonary disease susceptibility and lung cancer risk but did not test interactions between germline variants and smoking/environment in the dataset.</td>
                        </tr>
                        <tr>
                            <td><strong>testing_or_selection_bias</strong></td>
                            <td>Authors acknowledge selection and treatment biases: study was retrospective, single-institution; during the period most patients with severe pulmonary fibrosis or squamous cell carcinoma were excluded from EGFR mutation testing; indications for therapy and selection of treatment were not uniform; the cohort was somewhat younger and included more females and fewer never-smokers and fewer squamous cancers compared with their previously published lung cancer cohort. Small sample size precluded multivariate adjustment.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_tki_response_by_ethnicity</strong></td>
                            <td>Not reported. All patients in the cohort were treated in Japan (ethnically Japanese); no inter-ethnic comparisons were made. Within the mutation-positive cohort treated with gefitinib (n=43), median survival after gefitinib was 797 days (overall) and no significant difference in survival between never-smokers and smokers (797 days versus not reached; P = 0.96).</td>
                        </tr>
                        <tr>
                            <td><strong>methods_key_details</strong></td>
                            <td>EGFR mutation detection: peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp method targeting known sensitizing mutations (G719C/S/A, L858R, L861Q, exon 19 deletions) and T790M. Chest HRCT at diagnosis classified lungs as normal, emphysema, or fibrosis based on prespecified radiographic criteria. Statistical analysis used chi-square or Fisher's exact tests for categorical comparisons and Kaplan-Meier + log-rank for survival. No multivariate modeling performed due to sample size.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>Authors propose that smokers with emphysema or fibrosis may be more susceptible to smoking-related inflammation, and that NSCLC arising in smokers with normal lungs may have similar biology to tumors in never-smokers (and thus similar EGFR mutation prevalence). They suggest that overlapping/associated genetic variants implicated in smoking-related inflammation may underlie differences in both pulmonary disease susceptibility and EGFR mutation frequency, but they do not provide molecular data to support these mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_null_results</strong></td>
                            <td>Within patients with normal chest CT, EGFR mutation frequency did not differ between smokers and never-smokers (32.1% vs 37.7%, P = 0.5698), indicating that smoking history alone does not explain EGFR mutation prevalence in that radiographic subgroup. Also, age was not significantly associated with EGFR mutation (P = 0.5156).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_conflicts</strong></td>
                            <td>Limitations stated by authors: observational uncontrolled retrospective design, single institution, selection/treatment biases (exclusion of many severe fibrosis and squamous cases from testing), small sample size preventing multivariate analysis, nonuniform indications for therapy; these limit causal inference and generalizability. Authors declared no conflicts of interest.</td>
                        </tr>
                        <tr>
                            <td><strong>notable_quotes</strong></td>
                            <td>"Although demographic and clinical factors such as East-Asian race, female gender, nonsmoking status, and adenocarcinoma were shown to be predictive of the efficacy of gefitinib..." (Introduction).
"The frequency of EGFR mutation in patients with normal lungs on chest CT was not different between smokers and never-smokers." (Summary/Conclusion).</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy <em>(Rating: 2)</em></li>
                <li>Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial <em>(Rating: 2)</em></li>
                <li>Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR <em>(Rating: 2)</em></li>
                <li>Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 <em>(Rating: 1)</em></li>
                <li>A variant associated with nicotine dependence, lung cancer and peripheral arterial disease <em>(Rating: 1)</em></li>
                <li>Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib <em>(Rating: 1)</em></li>
                <li>Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>